Recent Updates
Recently added Catalysts
IPHA Positive Sentiment

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Key Takeaway: Innate Pharma SA has released its consolidated financial results for the first half of 2026. The company highlighted its strategic partnership with Sobi and emphasized the importance of 2026 as a year of execution. CEO Jonathan Dickinson noted the strengthening of the company's financial position.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innate Pharma has strengthened its financial position.
  • The strategic partnership with Sobi is a significant development.
  • The company is focused on execution in 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7.6%
average across 4 past catalysts
Lead asset
IPH2101
Phase 2 · Smoldering Multiple Myeloma

Full Press Release Details

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. “2026 continues to be an important year of execution for Innate, marked by our strategic partnership with Sobi and the strengthening of our financial position,” said Jonathan Dickinson, CEO of Innate P

Frequently Asked Questions

What did Innate Pharma report for H1 2026?

Innate Pharma reported its consolidated financial results for the first half of 2026.

Who is the CEO of Innate Pharma?

The CEO of Innate Pharma is Jonathan Dickinson.

What strategic partnership did Innate Pharma announce?

Innate Pharma announced a strategic partnership with Sobi.

What is significant about 2026 for Innate Pharma?

2026 is marked as an important year of execution for Innate Pharma.

Last updated: Sep 17, 2026